{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T10:44:41Z","timestamp":1793357081374,"version":"4.5.0"},"reference-count":72,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Kidney Disease and Health"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1053\/j.akdh.2024.04.004","type":"journal-article","created":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T09:06:09Z","timestamp":1722243969000},"page":"299-308","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Membranous Nephropathy: Updates on Management"],"prefix":"10.1053","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1401-8159","authenticated-orcid":false,"given":"Joyita","family":"Bharati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dia Rose","family":"Waguespack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1482-4089","authenticated-orcid":false,"suffix":"Jr.","given":"Laurence H.","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1053\/j.akdh.2024.04.004_bib1","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1681\/ASN.2019050538","article-title":"Detection of PLA2R autoantibodies before the diagnosis of membranous nephropathy","volume":"31","author":"Burbelo","year":"2020","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.akdh.2024.04.004_bib2","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1681\/ASN.2009080861","article-title":"Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy","volume":"21","author":"Polanco","year":"2010","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.akdh.2024.04.004_bib3","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1038\/ki.1995.453","article-title":"A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy","volume":"48","author":"Ponticelli","year":"1995","journal-title":"Kidney Int"},{"issue":"6","key":"10.1053\/j.akdh.2024.04.004_bib4","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1681\/ASN.2007020166","article-title":"A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy","volume":"18","author":"Jha","year":"2007","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"10.1053\/j.akdh.2024.04.004_bib5","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1681\/ASN.2020111583","article-title":"Primary nephrotic syndrome and risks of ESKD, cardiovascular events, and death: the Kaiser permanente nephrotic syndrome study","volume":"32","author":"Go","year":"2021","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.akdh.2024.04.004_bib6","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/ki.2011.312","article-title":"Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis","volume":"81","author":"Barbour","year":"2012","journal-title":"Kidney Int"},{"issue":"6","key":"10.1053\/j.akdh.2024.04.004_bib7","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1038\/ki.2013.476","article-title":"Personalized prophylactic anticoagulation decision analysis in patients with membranous nephropathy","volume":"85","author":"Lee","year":"2014","journal-title":"Kidney Int"},{"issue":"7","key":"10.1053\/j.akdh.2024.04.004_bib8","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1177\/10600280221129348","article-title":"Direct oral anticoagulants versus warfarin for venous thromboembolism prophylaxis in patients with nephrotic syndrome: a retrospective cohort study","volume":"57","author":"Tijani","year":"2023","journal-title":"Ann Pharmacother"},{"issue":"1","key":"10.1053\/j.akdh.2024.04.004_bib9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1053\/j.akdh.2024.04.004_bib10","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1681\/ASN.2014050502","article-title":"Identification of a major epitope recognized by PLA2R autoantibodies in primary membranous nephropathy","volume":"26","author":"Fresquet","year":"2015","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.akdh.2024.04.004_bib11","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1681\/ASN.2014111061","article-title":"Epitope spreading of autoantibody response to PLA2R associates with poor prognosis in membranous nephropathy","volume":"27","author":"Seitz-Polski","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.akdh.2024.04.004_bib12","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1681\/ASN.2019030273","article-title":"Clinical relevance of domain-specific phospholipase A2 receptor 1 antibody levels in patients with membranous nephropathy","volume":"31","author":"Reinhard","year":"2020","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.akdh.2024.04.004_bib13","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-15383-w","article-title":"The genetic architecture of membranous nephropathy and its potential to improve non-invasive diagnosis","volume":"11","author":"Xie","year":"2020","journal-title":"Nat Commun"},{"issue":"12","key":"10.1053\/j.akdh.2024.04.004_bib14","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1681\/ASN.2016010093","article-title":"Long-term exposure to air pollution and increased risk of membranous nephropathy in China","volume":"27","author":"Xu","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"10.1053\/j.akdh.2024.04.004_bib15","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.2215\/CJN.02930322","article-title":"Toxic occupational exposures and membranous nephropathy","volume":"17","author":"Cremoni","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.akdh.2024.04.004_bib16","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.kint.2023.07.024","article-title":"Introduction of a novel chimeric active immunization mouse model of PLA2R1-associated membranous nephropathy","volume":"104","author":"Tomas","year":"2023","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.akdh.2024.04.004_bib17","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.kint.2018.10.021","article-title":"Noninvasive diagnosis of primary membranous nephropathy using phospholipase A2 receptor antibodies","volume":"95","author":"Bobart","year":"2019","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.akdh.2024.04.004_bib18","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1681\/ASN.2016070776","article-title":"A proposal for a serology-based approach to membranous nephropathy","volume":"28","author":"De Vriese","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"10.1053\/j.akdh.2024.04.004_bib19","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1681\/ASN.2010111125","article-title":"Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy","volume":"22","author":"Beck","year":"2011","journal-title":"J Am Soc Nephrol"},{"issue":"4S","key":"10.1053\/j.akdh.2024.04.004_bib20","first-page":"S1","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","year":"2021","journal-title":"Kidney Int"},{"key":"10.1053\/j.akdh.2024.04.004_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.800242","article-title":"How times have changed! A Cornucopia of antigens for membranous nephropathy","volume":"12","author":"Caza","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"10.1053\/j.akdh.2024.04.004_bib22","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.kint.2019.09.014","article-title":"Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy","volume":"97","author":"Sethi","year":"2020","journal-title":"Kidney Int"},{"issue":"6","key":"10.1053\/j.akdh.2024.04.004_bib23","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1681\/ASN.2018080852","article-title":"Exostosin 1\/exostosin 2-associated membranous nephropathy","volume":"30","author":"Sethi","year":"2019","journal-title":"J Am Soc Nephrol"},{"issue":"20","key":"10.1053\/j.akdh.2024.04.004_bib24","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMc1511702","article-title":"A mechanism for cancer-associated membranous nephropathy","volume":"374","author":"Hoxha","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1053\/j.akdh.2024.04.004_bib25","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.kint.2020.07.039","article-title":"NELL1 is a target antigen in malignancy-associated membranous nephropathy","volume":"99","author":"Caza","year":"2021","journal-title":"Kidney Int"},{"issue":"6","key":"10.1053\/j.akdh.2024.04.004_bib26","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.kint.2023.06.032","article-title":"Mayo clinic consensus report on membranous nephropathy: proposal for a novel classification","volume":"104","author":"Sethi","year":"2023","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.akdh.2024.04.004_bib27","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.kint.2022.09.011","article-title":"False positivity for PLA2R1 antibody measured by ELISA in a nephrotic patient with no membranous nephropathy","volume":"103","author":"Hoxha","year":"2023","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.akdh.2024.04.004_bib28","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.kint.2022.11.004","article-title":"False-positive anti-PLA2R ELISA testing in patients with diabetes mellitus","volume":"103","author":"Caza","year":"2023","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.akdh.2024.04.004_bib29","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1681\/ASN.2020071082","article-title":"New \u201cantigens\u201d in membranous nephropathy","volume":"32","author":"Sethi","year":"2021","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.akdh.2024.04.004_bib30","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.kint.2021.03.028","article-title":"A conceptual framework linking immunology, pathology, and clinical features in primary membranous nephropathy","volume":"100","author":"Lerner","year":"2021","journal-title":"Kidney Int"},{"issue":"6","key":"10.1053\/j.akdh.2024.04.004_bib31","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1681\/ASN.2013040430","article-title":"Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy","volume":"25","author":"Hoxha","year":"2014","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"10.1053\/j.akdh.2024.04.004_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0110681","article-title":"PLA2R antibody levels and clinical outcome in patients with membranous nephropathy and non-nephrotic range proteinuria under treatment with inhibitors of the renin-angiotensin system","volume":"9","author":"Hoxha","year":"2014","journal-title":"PLoS One"},{"issue":"10","key":"10.1053\/j.akdh.2024.04.004_bib33","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1681\/ASN.2014070640","article-title":"Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy","volume":"26","author":"Ruggenenti","year":"2015","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.akdh.2024.04.004_bib34","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.kint.2017.12.019","article-title":"Immunological remission in PLA2R-antibody-associated membranous nephropathy: cyclophosphamide versus rituximab","volume":"93","author":"van de Logt","year":"2018","journal-title":"Kidney Int"},{"issue":"8","key":"10.1053\/j.akdh.2024.04.004_bib35","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/j.ekir.2023.05.009","article-title":"Rituximab in patients with primary membranous nephropathy with high immunologic risk","volume":"8","author":"Naik","year":"2023","journal-title":"Kidney Int Rep"},{"issue":"1","key":"10.1053\/j.akdh.2024.04.004_bib36","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1681\/ASN.2016040449","article-title":"Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up","volume":"28","author":"Dahan","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"10.1053\/j.akdh.2024.04.004_bib37","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.2215\/CJN.0000000000000237","article-title":"Anti-PLA2R antibody levels and clinical risk factors for treatment Nonresponse in membranous nephropathy","volume":"18","author":"Barbour","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.akdh.2024.04.004_bib38","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/ki.1997.127","article-title":"Validation of a predictive model of idiopathic membranous nephropathy: its clinical and research implications","volume":"51","author":"Cattran","year":"1997","journal-title":"Kidney Int"},{"issue":"3","key":"10.1053\/j.akdh.2024.04.004_bib39","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.kint.2018.10.024","article-title":"Novel ELISA for thrombospondin type 1 domain-containing 7A autoantibodies in membranous nephropathy","volume":"95","author":"Zaghrini","year":"2019","journal-title":"Kidney Int"},{"issue":"3","key":"10.1053\/j.akdh.2024.04.004_bib40","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1093\/ndt\/gfu306","article-title":"Predictors of response and relapse in patients with idiopathic membranous nephropathy treated with tacrolimus","volume":"30","author":"Caro","year":"2015","journal-title":"Nephrol Dial Transplant"},{"issue":"12","key":"10.1053\/j.akdh.2024.04.004_bib41","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/j.ekir.2019.09.005","article-title":"Treatment patterns Among adults and Children with membranous nephropathy in the cure Glomerulonephropathy Network (CureGN)","volume":"4","author":"O\u2019Shaughnessy","year":"2019","journal-title":"Kidney Int Rep"},{"issue":"12","key":"10.1053\/j.akdh.2024.04.004_bib42","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1681\/ASN.2015010091","article-title":"Complete and partial remission as surrogate end points in membranous nephropathy","volume":"26","author":"Thompson","year":"2015","journal-title":"J Am Soc Nephrol"},{"issue":"9337","key":"10.1053\/j.akdh.2024.04.004_bib43","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0140-6736(02)11042-7","article-title":"Rituximab for idiopathic membranous nephropathy","volume":"360","author":"Remuzzi","year":"2002","journal-title":"Lancet"},{"issue":"5","key":"10.1053\/j.akdh.2024.04.004_bib44","doi-asserted-by":"crossref","first-page":"932","DOI":"10.2215\/CJN.01180307","article-title":"Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy","volume":"2","author":"Cravedi","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"10.1053\/j.akdh.2024.04.004_bib45","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1681\/ASN.2012020181","article-title":"Rituximab in idiopathic membranous nephropathy","volume":"23","author":"Ruggenenti","year":"2012","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.akdh.2024.04.004_bib46","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/sj.ki.5002628","article-title":"Rituximab treatment of idiopathic membranous nephropathy","volume":"73","author":"Fervenza","year":"2008","journal-title":"Kidney Int"},{"issue":"12","key":"10.1053\/j.akdh.2024.04.004_bib47","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.2215\/CJN.05080610","article-title":"Rituximab therapy in idiopathic membranous nephropathy: a 2-year study","volume":"5","author":"Fervenza","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.akdh.2024.04.004_bib48","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.kint.2020.10.014","article-title":"The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy","volume":"99","author":"Fern\u00e1ndez-Ju\u00e1rez","year":"2021","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.akdh.2024.04.004_bib49","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1681\/ASN.2020071091","article-title":"Rituximab or cyclophosphamide in the treatment of membranous nephropathy: the RI-CYCLO randomized trial","volume":"32","author":"Scolari","year":"2021","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.akdh.2024.04.004_bib50","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa1814427","article-title":"Rituximab or cyclosporine in the treatment of membranous nephropathy","volume":"381","author":"Fervenza","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1053\/j.akdh.2024.04.004_bib51","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.2215\/CJN.11791018","article-title":"High-dose rituximab and early remission in PLA2R1-related membranous nephropathy","volume":"14","author":"Seitz-Polski","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"10.1053\/j.akdh.2024.04.004_bib52","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1093\/ndt\/gfz041","article-title":"Rituximab bioavailability in primary membranous nephropathy","volume":"34","author":"Boyer-Suavet","year":"2019","journal-title":"Nephrol Dial Transplant"},{"issue":"9","key":"10.1053\/j.akdh.2024.04.004_bib53","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1681\/ASN.2016091022","article-title":"Safety of rituximab compared with steroids and cyclophosphamide for idiopathic membranous nephropathy","volume":"28","author":"van den Brand","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"10.1053\/j.akdh.2024.04.004_bib54","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1093\/ndt\/gfy049","article-title":"Rituximab versus the modified Ponticelli regimen in the treatment of primary membranous nephropathy: a Health Economic Model","volume":"33","author":"Hamilton","year":"2018","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1053\/j.akdh.2024.04.004_bib55","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ekir.2016.05.002","article-title":"Membranous nephropathy: pilot study of a novel regimen combining cyclosporine and Rituximab","volume":"1","author":"Waldman","year":"2016","journal-title":"Kidney Int Rep"},{"issue":"6","key":"10.1053\/j.akdh.2024.04.004_bib56","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1053\/j.ajkd.2021.04.014","article-title":"Combination of rituximab, low-dose cyclophosphamide, and prednisone for primary membranous nephropathy: a case series with extended follow up","volume":"78","author":"Zonozi","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.akdh.2024.04.004_bib57","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.3389\/fimmu.2019.03069","article-title":"Neutralizing anti-rituximab antibodies and relapse in membranous nephropathy treated with rituximab","volume":"10","author":"Boyer-Suavet","year":"2020","journal-title":"Front Immunol"},{"issue":"4","key":"10.1053\/j.akdh.2024.04.004_bib58","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.ekir.2021.01.022","article-title":"Analysis and management of rituximab resistance in PLA2R1-associated membranous nephropathy","volume":"6","author":"Teisseyre","year":"2021","journal-title":"Kidney Int Rep"},{"issue":"1","key":"10.1053\/j.akdh.2024.04.004_bib59","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.kint.2018.08.045","article-title":"Retreatment with rituximab for membranous nephropathy with persistently elevated titers of anti-phospholipase A2 receptor antibody","volume":"95","author":"Dahan","year":"2019","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.akdh.2024.04.004_bib60","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41572-021-00303-z","article-title":"Membranous nephropathy","volume":"7","author":"Ronco","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"10.1053\/j.akdh.2024.04.004_bib61","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.ekir.2022.12.003","article-title":"Antibody-guided therapy in phospholipase A2 receptor-associated membranous nephropathy","volume":"8","author":"Vink","year":"2023","journal-title":"Kidney Int Rep"},{"issue":"1","key":"10.1053\/j.akdh.2024.04.004_bib62","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1080\/0886022X.2022.2033265","article-title":"Negative anti-phospholipase A2 receptor antibody status at three months predicts remission in primary membranous nephropathy","volume":"44","author":"Stefan","year":"2022","journal-title":"Ren Fail"},{"issue":"3","key":"10.1053\/j.akdh.2024.04.004_bib63","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1681\/ASN.2015111262","article-title":"Membranous nephropathy: Quantifying remission duration on outcome","volume":"28","author":"Cattran","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.akdh.2024.04.004_bib64","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1111\/j.1523-1755.2004.00873.x","article-title":"Idiopathic membranous nephropathy: definition and relevance of a partial remission","volume":"66","author":"Troyanov","year":"2004","journal-title":"Kidney Int"},{"issue":"5","key":"10.1053\/j.akdh.2024.04.004_bib65","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.ekir.2020.02.1030","article-title":"Serum albumin at partial remission predicts outcomes in membranous nephropathy","volume":"5","author":"Lee","year":"2020","journal-title":"Kidney Int Rep"},{"issue":"2","key":"10.1053\/j.akdh.2024.04.004_bib66","doi-asserted-by":"crossref","first-page":"c145","DOI":"10.1159\/000324762","article-title":"Relapse or worsening in idiopathic membranous nephropathy can occur even though the glomerular immune deposits have been eradicated","volume":"119","author":"Barnes","year":"2011","journal-title":"Nephron Clin Pract"},{"issue":"8","key":"10.1053\/j.akdh.2024.04.004_bib67","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/ckj\/sfad041","article-title":"Future landscape for the management of membranous nephropathy","volume":"16","author":"Caravaca-Font\u00e1n","year":"2023","journal-title":"Clin Kidney J"},{"issue":"10","key":"10.1053\/j.akdh.2024.04.004_bib68","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1097\/TP.0000000000002758","article-title":"Membranous nephropathy Posttransplantation: an update of the Pathophysiology and management","volume":"103","author":"Leon","year":"2019","journal-title":"Transplantation"},{"key":"10.1053\/j.akdh.2024.04.004_bib69","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.3389\/fimmu.2019.01326","article-title":"Membranous nephropathy (MN) recurrence after renal transplantation","volume":"10","author":"Passerini","year":"2019","journal-title":"Front Immunol"},{"issue":"5","key":"10.1053\/j.akdh.2024.04.004_bib70","doi-asserted-by":"crossref","first-page":"790","DOI":"10.2215\/CJN.04120609","article-title":"Beneficial effect of rituximab in the treatment of recurrent idiopathic membranous nephropathy after kidney transplantation","volume":"5","author":"Sprangers","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.akdh.2024.04.004_bib71","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1681\/ASN.2021101323","article-title":"Recurrence of anti-Semaphorin 3B-Mediated membranous nephropathy after kidney transplantation","volume":"33","author":"Fila","year":"2022","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"10.1053\/j.akdh.2024.04.004_bib72","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1172\/JCI85265","article-title":"Autoantibodies against thrombospondin type 1 domain-containing 7A induce membranous nephropathy","volume":"126","author":"Tomas","year":"2016","journal-title":"J Clin Invest"}],"container-title":["Advances in Kidney Disease and Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949813924000764?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949813924000764?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T22:40:29Z","timestamp":1722724829000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949813924000764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":72,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S2949813924000764"],"URL":"https:\/\/doi.org\/10.1053\/j.akdh.2024.04.004","relation":{},"ISSN":["2949-8139"],"issn-type":[{"value":"2949-8139","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Membranous Nephropathy: Updates on Management","name":"articletitle","label":"Article Title"},{"value":"Advances in Kidney Disease and Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.akdh.2024.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the National Kidney Foundation, Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}